SERUM INTERLEUKIN-18 AS A NOVEL BIOMARKER FOR DISEASE ACTIVITY OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS | ||||
| Journal of the Egyptian Society of Parasitology | ||||
| Article 18, Volume 49, Issue 1, April 2019, Page 145-152 PDF (529.77 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jesp.2019.68297 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| AMAL S. ELSHAL1; MOHAMED H. SHERIF2; AMAL B. ABDULSATTAR3; FATMA ELZAHRAA E. GOUDA2 | ||||
| 1Department of Medical Biochemistry, Faculty of Medicine, Zagazig University, Zagazig, Egypt. | ||||
| 2Department of Chemistry, Faculty of Science, Zagazig University, Zagazig, Egypt. | ||||
| 3Department of Rheumatology and Rehabilitation, Faculty of Medicine, Zagazig University, Zagazig, Egypt. | ||||
| Abstract | ||||
| Interleukin-18 (IL-18) is a vital cytokine, which mediated organ failure and elevated in autoimmune disorders as Systemic Lupus Erythematosus. This study investigated the importance role of IL-18 as a diagnostic marker for disease activity of systemic lupus erythematosus (SLE) and development of lupus nephritis (LN). This cross-sectional study was carried out on 41 SLE patients with LN, 31 lupus non-nephritis patients and 20 healthy controls. The IL-18 serum levels were measured by IL-18 ELISA kit, to evaluate the activity of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score. The results showed significant increase in serum IL-18 level in patients with LN (174.09±33.19) than both lupus non nephritis patients (9139.45±64.39) and healthy control (46.06±16.42), with significant correlation between IL-18 level and SLEDAI. | ||||
| Keywords | ||||
| interleukin-18; Systemic lupus erythematosus; disease activity; Lupus nephritis | ||||
|
Statistics Article View: 154 PDF Download: 175 |
||||
